Sage Therapeutics, Inc. announced the retirement of Kevin Starr from the company?s board of directors. Geno Germano has assumed the role of Chair of the Board of Directors. Mr. Starr led the early efforts to launch Sage Therapeutics, served as CEO prior to the company?s initial public offering, and served as Chair of the Board since Sage went public in 2014.

Mr. Starr co-founded Third Rock Ventures in 2007 and was a leader in the formation, development and business strategy of the firm?s portfolio companies as well as actively identifying and evaluating new investments. Mr. Germano is currently the President and Chief Executive Officer at Elucida Oncology and has served on Sage?s board of directors since 2016. He has over 30 years of experience in the pharmaceutical industry and a consistent track record of improving operating performance and increasing shareholder value across numerous leadership roles in multiple therapeutic categories and global markets at Intrexon, Pfizer, Wyeth, and Johnson & Johnson.